Newscast – Page 139 – media

Potential weapons for the battle against antibiotic resistance discovered

Scientists at the UNC School of Medicine have found that a bacterium can become much more or less susceptible to an antibiotic depending on the specific bacterial community in its midst.
- Source: sciencedaily
- 503
- December 6, 2017
aeruginosa antibiotics bacterium Researches
Infant CCHD deaths cut by 33% after mandatory pulse oximetry testing

Infant deaths from critical congenital heart disease (CCHD) declined by 33.4 percent in eight states that mandated pulse oximetry screening for newborns, according to a study published online Dec. 5 in JAMA.
- Source: cardiovascularbusiness
- 401
- December 6, 2017
CCHD Market Views
Neon Therapeutics Completes $106 Million Crossover Series B Financing

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen therapies, today announced the successful completion of an additional $36 million extension to its Series B financing which, combined with $70 million announced in January 2017, brings the total raised during this Series B crossover round to $106 million.
- Source: Businesswire
- 457
- December 6, 2017
immuno-oncology Market Views neoantigen
Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1 OZEMPIC® is administered once weekly, on the same day each week, and can be taken any time of the day, with or without meals.
- Source: medicalxpress
- 600
- December 6, 2017
diabetes FDA Novo Nordisk OZEMPIC®
Men with HPV are 20 times more likely to be reinfected after one year

The study, published December 5 in the Proceedings of the National Academy of Sciences, highlights the importance of vaccination for preventing the spread of HPV in young men before they become sexually active. Vaccination could potentially prevent reinfection in older men who have already contracted the virus.
- Source: medicalxpress
- 670
- December 6, 2017
cancer HPV Researches vaccination
CRISPR/Cas9 gene editing can be used to eliminate entire chromosomes — a Q&A

As is well known, CRISPR/Cas9 is an effective tool for gene editing, and this method has been widely used for editing genes or genomic regions by targeting specific single-guide RNA (sgRNAs). We initially planned to use the CRISPR/Cas9 system to study the biological functions of Y chromosome genes.
- Source: biomedcentral
- 623
- December 5, 2017
CAS9 chromosome CRISPR gene Researches
New Drugs Could Prevent Migraine Headaches For Some People

People who experience frequent migraines may soon have access to a new class of drugs. In a pair of large studies, two drugs that tweak brain circuits involved in migraine each showed they could reduce the frequency of attacks without causing side effects, researchers report in the New England Journal of Medicine.
- Source: npr
- 543
- December 5, 2017
brain drug epilepsy Researches
Researchers show aspirin added to cancer drug improves effectiveness

Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.
- Source: medicalxpress
- 620
- December 5, 2017
aspirin cancer colorectal lung pancreatic Researches
HeartFlow’s estimated $150m Series E would make it medtech’s latest unicorn

A reported Series E round for HeartFlow, estimated at $150 million, would value the company at more than $1 billion, vaulting it into unicorn territory.
- Source: Massdevice
- 2,038
- December 5, 2017
coronary lesions Market Views
Astellas Takes Out Massachusetts’ Biotech Mitobridge in $390M Deal

Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013. Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. The most advanced program from the collaboration is MA-0211, which is presently in Phase I clinical trials for Duchenne muscular dystrophy (DMD). Astellas is an equity investor in Mitobridge already, and is paying $165.5 million in cash in addition to the $60 million in equity it already owns. There is also an additional $225 million in potential milestone payments. John Carroll, with Endpoints News, writes, “For years now, Salk’s Ron Evans—a celebrated serial entrepreneur in scientific circles—has been concentrating on the potential of a new pathway for turning your average couch potato rodent into Mighty Mouse—without exercise…. A couple of ...
- Source: biospace
- 725
- December 5, 2017
acquisition Astellas Clinical Trials Duchenne muscular dystrophy Market Views Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.